Opsona Therapeutics is developing a robust pipeline of new lead molecules that suppress inflammatory immune responses. Some of these molecules block specific Toll-like receptor signaling, which is the first event in inflammatory immune responses. Opsona Therapeutics is also discovering new molecules and targets that control the first events that trigger the inflammatory immune responses. In addition Opsona is looking at innovative ways to modulate the immune system regulators to treat cancer and infectious disease. More information on Opsona's pipeline & partnering activities will be made available shortly.
